Aktienanalyse zu Mustang Bio Inc (MBIO)MBIOMustang Bio Inc

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs into potential cures for cancers and autoimmune diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. It is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. It has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Mustang Bio Inc is not a good buy right now due to its significantly negative financial performance and poor technical indicators. The current price is $0.54, and the 1-year change is a staggering -64.86%. Additionally, the RSI is at 25.05, indicating that the stock is oversold, but this is not a strong enough signal to warrant a buy given the overall financial health of the company.

1 analysts cover MBIO: 1 rate it Buy, 0 Hold and 0 Sell.